A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for ...

A personalized DNA vaccine for glioblastoma, an aggressive and incurable brain cancer, appears safe and shows early signs of ...

A personalized vaccine to treat glioblastoma, a fast-growing and incurable brain cancer that affects four in 100,000 people ...

A Phase 1 trial shows a personalized DNA vaccine (GNOS-PV01) is safe and doubles survival rates for aggressive glioblastoma.

Glioblastoma vaccine shows promise by activating immune response and improving survival in a phase 1 trial at Siteman Cancer Center.

Participants in a clinical trial lived longer years longer after increased immune response to glioblastoma slowed progression ...

Glioblastoma is the most aggressive primary brain cancer in adults, killing most patients within two years of diagnosis ...

Scientists are creating a glioblastoma 'tumor on a chip'—a tiny living system capable of mimicking the key features of the ...

CNS Pharmaceuticals (NASDAQ:CNSP) is back on every biotech watchlist after a 242.36% one-week ramp tied to its Berubicin ...

Survival rate surpasses historical outcomes in a small phase I study ...